also found that HVEM was expressed in 65%-98.3% of melanomas by immunohistochemistry, BTLA was expressed in CD8+ tumor-infiltrating Lymphocytes (TILs) in 11.1% of patients, and HVEM was more widely expressed than PD-L1 by flow cytometry (43% vs 1.6%) (26). This evidence concerns the gene TNFRSF14 and neoplasm.